XKR7 inhibitors are chemical compounds designed to target and inhibit the activity of the XKR7 protein, a member of the XK-related (XKR) family, which is involved in regulating cellular membrane dynamics. XKR7, like other proteins in the XKR family, is believed to play a role in processes such as phospholipid translocation and membrane reorganization, which are essential for maintaining the structural integrity and function of cellular membranes. XKR7 is likely involved in regulating the movement of phospholipids between the inner and outer layers of the lipid bilayer, an important process in cell membrane maintenance. This protein is also thought to contribute to cellular mechanisms related to membrane asymmetry and remodeling, which are critical during cellular activities such as cell division, apoptosis, and response to environmental stressors.
Inhibitors of XKR7 work by binding to key functional or regulatory sites on the protein, preventing it from executing its role in membrane dynamics and phospholipid translocation. This inhibition can disrupt the normal movement of phospholipids, which may alter membrane fluidity and asymmetry, affecting processes like signal transduction, apoptosis regulation, and other membrane-related cellular activities. Inhibiting XKR7 could also influence how cells respond to external cues that require membrane changes, such as during cell migration or cellular stress responses. The structural and functional study of XKR7 inhibitors helps reveal their impact on the delicate balance of membrane organization and the broader cellular processes that depend on precise membrane function. Understanding these interactions is crucial for exploring how XKR7 regulates the dynamic nature of cellular membranes and how its inhibition affects overall cellular physiology.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Statins may indirectly influence XKR7 by altering cholesterol synthesis and membrane lipid composition, potentially affecting XKR7's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, a PI3K/Akt/mTOR inhibitor, could impact XKR7 indirectly through cellular signaling pathways related to membrane dynamics and protein trafficking. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine might indirectly affect XKR7 by modulating calcium signaling, which can be relevant for membrane-associated proteins. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A may indirectly affect XKR7 through its role in chromatin remodeling and gene expression, potentially impacting XKR7's expression or function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitors like Bortezomib could indirectly influence XKR7 by modulating protein degradation pathways. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine, an autophagy modulator, could have indirect implications for XKR7 through its role in cellular degradation processes. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082, an NF-κB pathway inhibitor, may indirectly impact XKR7 by affecting cellular signaling involved in inflammation and stress responses. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib might indirectly impact XKR7 by modulating JAK/STAT signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126, an inhibitor of the ERK/MAPK pathway, might indirectly affect XKR7 by influencing cell differentiation and growth pathways. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG, an HSP90 inhibitor, could affect XKR7 indirectly by impacting protein folding and stability. | ||||||